Tacrolimus: The drug for the turn of the millennium?

Archives of Dermatology

Volumn 135, Issue 5, 1999, Pages 574-580

  Ruzicka, Thomas ^a   Assmann, Till ^a   Homey, Bernhard ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ATOPIC DERMATITIS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HUMAN; MEDICAL LITERATURE; PRIORITY JOURNAL; PUBLICATION; REVIEW; SKIN INFLAMMATION;

DERMATITIS, ATOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PSORIASIS; SKIN DISEASES; TACROLIMUS;

EID: 0032953631     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.135.5.574     Document Type: Review

References (76)

1. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13:136-142.
2. Ruzicka T, Bieber T, Schöpf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med. 1997;337:816-821.
3. Lauerma AI, Maibach HI. Topical FK506: clinical potential or laboratory curiosity? Dermatology. 1994;188:173-176.
4. Homey B, Schuppe HC, Assmann T, et al. A local lymph node assay to analyse immunosuppressive effects of topically applied drugs. Eur J Pharmacol. 1997; 325:199-207.
5. Lauerma AI, Maibach HI, Granlund H, Erkko P, Kartamaa M, Stubb S. Inhibition of contact allergy reactions by topical FK506. Lancet. 1992;340:556.
6. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces, II: immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987;40:1256-1265.
7. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature. 1992;357:695-697.
8. Sigal NH, Dumont FJ. Cydosporine A, FK506 and rapamycin: pharmacological probes of lymphocyte signal transduction. Annu Rev Immunol. 1992;10:519.
9. Rao A. NF-ATp: a transcription factor required for the co-ordinate induction of several cytokine genes. Immunol Today. 1994;15:274.
10. Casolaro V, Cirillo R, Genovese A, Formisano S, Ayala F, Marone G. Human basophil releasability, IV: changes in basophil releasability in patients with chronic urticaria. J Immunol Res. 1989;1:67-73.
11. Schubert C, Christophers E. Mast cells and macrophages in early relapsing psoriasis. Arch Dermatol Res. 1985;277:352-358.
12. Dvork HF, Hammond ME, Colvin RB, Manseau EJ, Goodwin J. Systemic expression of cutaneous basophil hypersensitivity. J Immunol. 1977;118:1549-1557.
13. Marone G, Giugliano R, Lembo G, Ayala F. Human basophil releasability, II: changes in basophil releasability in patients with atopic dermatitis. J Invest Dermatol. 1986; 87:19-23.
14. de Paulis A, Stellato C, Cirillo R, Ciccarelli A, Oriente A, Marone G. Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol. 1992; 99:723-728.
15. Eberlein-König B, Ruzicka T, Michel G, Przybilla B. Modulation of histamine release in vitro by FK506 and interleukin-3 is determined by sequence of incubation. Arch Dermatol Res. 1997;289:606-608.
16. Homey B, Assmann T, Lauerma AI, et al. Topical FK506: suppression of Th1 and Th2 cytokine induction in lymph node cells in vivo. J Invest Dermatol. 1996; 107:476.
17. Homey B, Assmann T, Vohr HW, et al. Topical FK506 suppresses interleukin-12 and costimulatory molecule expression in vivo. J Invest Dermatol. 1997;109: 454.
18. Panhans A, Bieber T. FK506 (tacrolimus) impairs the phenotypic and functional differentiation of human epidermal Langerhans cells. J Invest Dermatol. 1996; 107:485.
19. Wollenberg A, Regele D, Sharma S, Haberstok J, Panhans A, Bieber T. Topical tacrolimus (FK506) treatment leads to profound alterations of the antigen presenting cells in lesional atopic dermatitis skin [abstract]. J Invest Dermatol. 1996; 107:468.
20. Schulz BS, Michel G, Wagner S, et al. Increased expression of epidermal IL-8 receptor in psoriasis: down-regulation by FK-506 in vitro. J Immunol. 1993;151: 4399-4406.
21. Lemster BH, Carroll PB, Rilo HR, Johnson N, Nikaein A, Thomson AW. IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. Clin Exp Immunol. 1995;99:148-154.
22. Michel G, Auer H, Kemeny L, Bocking A, Ruzicka T. Antioncogene P53 and mitogenic cytokine interleukin-8 aberrantly expressed in psoriatic skin are inversely regulated by the antipsoriatic drug tacrolimus. Biochem Pharmacol. 1996; 51:1315-1320.
23. Lauerma AI, Stein B, Lee HL, Homey B, Bloom E, Maibach HI. Topical tacrolimus (FK506): percutaneous absorption and effect on allergic and irritant contact dermatitis [abstract]. J Invest Dermatol. 1993;110:491.
24. Lauerma AI, Surber C, Maibach HI. Absorption of topical tacrolimus (FK506) in vitro through human skin: comparison with cyclosporin A. Skin Pharmacol. 1997; 10:230-234.
25. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992;20:753-761.
26. Shiraga T, Matsuda H, Nagase K, et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol. 1994;47:727-735.
27. Iwasaki K, Shiraga T, Matsuda H, et al. Further metabolism of FK506 (tacrolimus): identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab Dispos. 1995;23:28-34.
28. Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Abu-Elmagd K, Starzl TE. Tacrolimus (FK 506): a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol. 1992;128:781-785.
29. The European FK 506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol. 1996;132:419-423.
30. Sakane T, Mochizuki M, Inaba G, Masuda K. A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behçet's disease and allied conditions. Ryumachi. 1995;35:802-813.
31. Koga T, Yano T, Ichikawa Y, Oizumi K, Mochizuki M. Pulmonary infiltrates recovered by FK506 in a patient with Behçet's disease. Chest. 1993;104:309-311.
32. Abu Elmagd K, Jegasothy BV, Ackerman CD, et al. Efficacy of FK506 in the treatment of recalcitrant pyoderma gangrenosum. Transplant Proc. 1991;23: 3328-3329.
33. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol. 1997;92:876-879.
34. Nakagawa H, Etoh T, Ishibashi Y, et al. Tacrolimus ointment for atopic dermatitis [letter]. Lancet. 1994;344:883.
35. Aoyama H, Tabata N, Tanaka M, Uesugi Y, Tagami H. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br J Dermatol. 1995;133:494-496.
36. Sainsbury TS, Duncan JI, Whiting PH, et al. Differential effects of FK 506 and cyclosporine on hair regrowth in the DEBR model for alopecia areata. Transplant Proc. 1991;23:3332-3334.
37. Yamamoto S, Jiang H, Kato R. Stimulation of hair growth by topical application of FK506, a potent immunosuppressive agent. J Invest Dermatol. 1994;102: 160-164.
38. + T cells restores hair growth in the DEBR model for alopecia areata. Br J Dermatol. 1996;135:211-217.
39. Elder JT, Nair RP, Guo SW, Henseler T, Christophers E, Voorhees JJ. The genetics of psoriasis. Arch Dermatol. 1994;130:216-224.
40. White SH, Newcomer VD, Mickey MR, Terasaki PI. Disturbance of HL-A antigen frequency in psoriasis. N Engl J Med. 1972;287:740-743.
41. Ragaz A, Ackerman AB. Evolution, maturation, and regression of lesions of psoriasis: new observations and correlation of clinical and histologic findings. Am J Dermatopathol. 1979;1:199-214.
42. Eedy DJ, Burrows D, Bridges JM, Jones FG. Clearance of severe psoriasis after allogenic bone marrow transplantation [abstract]. BMJ. 1990;300:908.
43. Nicolas JF, Chamchick N, Thivolet J, Wijdenes J, Morel P, Revillard JP. CD4 antibody treatment of severe psoriasis. Lancet. 1991;338:321.
44. + T cells. Nature Med. 1997;3:183-188.
45. Peter RU, Ruzicka T. Cyclosporin A in der Therapie entzündlicher Dermatosen. Hautarzt. 1992;43:687-694.
46. Süss R, Al-Ayoubi M, Ruzicka T. Cyclosporine therapy in Behçet's disease. J Am Acad Dermatol. 1993;29:101-102.
47. Behçet H. Some observations on the clinical picture of the so-called triple symptom complex. Dermatologica. 1940;81:73-77.
48. Abu Elmagd K, van Thiel DH, Jegasothy BV, et al. Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506). Ann Intern Med. 1993;119:595-598.
49. Diepgen TL, Fartasch M. Recent epidemiological and genetic studies in atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1992;176:13-18.
50. Cooper KD. Atopic dermatitis: recent trends in pathogenesis and therapy. J Invest Dermatol. 1994;102:128-137.
51. Ruzicka T, Ring J, Przybilla B. Handbook of Atopic Eczema. Heidelberg, Germany: Springer Verlag; 1991.
52. Grewe M, Gyufko K, Schöpf E, Krutmann J. Lesional expression of interferon-gamma in atopic eczema. Lancet. 1994;343:25-26.
53. Bruynzeel-Koomen C, van Wichen DF, Toonstra J, Berrens L, Bruynzeel PL. The presence of IgE molecules on epidermal Langerhans cells in patients with atopic dermatitis. Arch Dermatol Res. 1986;278:199-205.
54. Bieber T, Rieger A, Neuchrist C, et al. Induction of Fc ∈ R2/CD23 on human epidermal Langerhans cells by human recombinant interleukin 4 and gamma interferon. J Exp Med. 1989;170:309-314.
55. van der Heijden FL, Joost van Neerven RJ, van Katwijk M, Bos JD, Kapsenberg ML. Serum-IgE-facilitated allergen presentation in atopic disease. J Immunol. 1993;150:3643-3650.
56. Bos JD, Kapsenberg ML, Smitt JH. Pathogenesis of atopic eczema. Lancet. 1994; 343:1338-1341.
57. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1989;144:13-14.
58. Perret C, Wiesner Menzel L, Happle R. Immunohistochemical analysis of T-cell subsets in the peribulbar and intrabulbar infiltrates of alopecia areata. Acta Derm Venereol. 1984;64:26-30.
59. Whiting PH. Acute and chronic nephrotoxicity associated with immunosuppressive drugs. Curr Opin Nephrol Hypertens. 1994;3:174-181.
60. Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation: a comparison between cyclosporine and FK506. Transplantation. 1994;58:170-178.
61. Taler SJ, Textor SC, Canzanello VJ, et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation. 1996;62:1588-1592.
62. Andoh TF, Burdmann EA, Fransechini N, Houghton DC, Bennett WM. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int. 1996;50:1110-1117.
63. Goodall T, Kind CN, Hammond TG. FK506-induced endothelin release by cultured rat mesangial cells. J Cardiovasc Pharmacol. 1995;26(suppl 3):482-485.
64. Moutabarrik A, Ishibashi M, Fukunaga M, et al. FK506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. Transplant Proc. 1991;23:3133-3136.
65. Shihab FS, Bennett WM, Tanner AM, Andoh TF. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation. 1997;64:1829-1837.
66. Katari SR, Magnone M, Shapiro R, et al. Clinical features of acute reversible tacrolimus (FK506) nephrotoxicity in kidney transplant recipients. Clin Transplant. 1997;11:237-242.
67. McKee M, Segev D, Wise B, et al. Initial experience with FK506 (tacrolimus) in pediatric renal transplant recipients. J Pediatr Surg. 1997;32:688-690.
68. Wijdicks EF, Wiesner RH, Dahlke LJ, Krom RA. FK506-induced neurotoxicity in liver transplantation. Ann Neurol. 1994;35:498-501.
69. DiMartini AF, Trzepacz PT, Daviss SR. Prospective study of FK506 side effects: anxiety or akathisia? Biol Psychiatry. 1996;40:407-411.
70. Steinmuller TM, Graf KJ, Schleicher J, et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism: a randomized trial. Transplantation. 1994;58:669-674.
71. Duncan JI. Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK506, and rapamycin. J Invest Dermatol. 1994;102:84-88.
72. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998;111:396-398.
73. Ruzicka T. Cyclosporin in less common immune-mediated skin diseases. Br J Dermatol. 1996;135(suppl 48):40-42.
74. Furukawa F, Imamura S, Takigawa M. FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-Ipr/Ipr mice. Arch Dermatol Res. 1995; 287:558-563.
75. Hoxtermann S, Nuchel C, Altmeyer P. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriais. Dermatology. 1998;196: 223-230.
76. Bacharach-Bauhles M, Pawlak FM, Matthes U, Joshi RK, Altmeyer P. Fumaric acid esters (FAEs) suppress CD15- and ODP-4-positive cells in psoriais. Acta Derm Venereol Suppl. 1994;186:79-82.